Weight Loss

It is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is being studied for its potential use in the treatment of obesity and type 2 diabetes.

In the context of weight loss, Tirzepatide has shown promise in clinical trials by helping people with obesity lose weight. It works by reducing appetite and increasing feelings of fullness, which can lead to decreased food intake and weight loss.

It is a medication that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of obesity. It contains semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist. This medication is used to assist people with obesity in losing weight when combined with a reduced-calorie diet and increased physical activity.